Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis

Herk‐Sukel, Myrthe P. P. van; Poll‐Franse, Lonneke V. van de; Voogd, Adri C.; Nieuwenhuijzen, Grard A. P.; Coebergh, Jan Willem; Herings, Ron M. C.

doi:10.1007/s10549-009-0724-3

Cited by 123 publications

(113 citation statements)

References 26 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…The present study had a higher percentage of adherent patients at the 1-and 2-year follow-up visits than in previous publications (11,13). The study population included 50% of the patients with breast cancer in Lund and was similar, with regard to age, ER, and PR status, to the 50% of patients with breast cancer in Lund who were not included.…”

Section: Discussionmentioning

confidence: 75%

“…Previous publications suggest nonadherence as high as 23.6% after the first year of follow-up (11,12). Nonadherence increases with each consecutive year (11,12).…”

Section: Introductionmentioning

confidence: 89%

“…The age cutoff points examined in relation to adherence were chosen in concordance with earlier publications (11,13,15,23,24). A BMI cutoff point at 25 kg/m 2 was used according to World Health Organization (WHO) classifications of overweight (34).…”

Section: Methodsmentioning

confidence: 99%

“…Previous publications suggest nonadherence as high as 23.6% after the first year of follow-up (11,12). Nonadherence increases with each consecutive year (11,12). Several studies report that nonadherence rates are close to 50% before the end of the recommended 5-year treatment period (11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

“…Nonadherence increases with each consecutive year (11,12). Several studies report that nonadherence rates are close to 50% before the end of the recommended 5-year treatment period (11)(12)(13). Tamoxifen users seem less adherent than AI users (12,14,15), possibly due to differing side effect profiles (4).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Clinical Profiles Predict Early Nonadherence to Adjuvant Endocrine Treatment in a Prospective Breast Cancer Cohort

Markkula

Hietala

Henningson

et al. 2012

Cancer Prevention Research

View full text Add to dashboard Cite

Nonadherence to adjuvant endocrine breast cancer treatment adversely affects disease-free and overall survival. Clinical predictors of nonadherence may allow for specific interventions to reduce nonadherence and improve survival. The aim was to investigate whether clinical characteristics predict nonadherence. Clinical characteristics and information on adherence were obtained from 417 patients with breast cancer in a population-based prospective cohort from southern Sweden using patient charts, pathology reports, and questionnaires filled out at the 1-and 2-year follow-up visits. At the 1-and 2-year follow-up visits, 36 (8.6%) and 33 (9.7%) patients were nonadherent, respectively. Thirteen of the nonadherent patients declined treatment and were never prescribed endocrine treatment. A body mass index (BMI) < 25 kg/m 2 , preoperative current smoking, and drinking alcohol less often than twice a month predicted nonadherence at the 1-year [relative risk (RR), 5.24; 95% confidence interval (CI), 2.75-9.97] and the 2-year visits (RR, 4.07; 95% CI, 2.11-7.84) in patients with at least two of these clinical characteristics. When low histologic grade (I) was added to the model, having at least two of these four clinical characteristics predicted nonadherence at the 1-year (RR, 4.94; 95% CI, 2.46-10.00) and the 2-year visits (RR, 4.74; 95% CI, 2.28-9.87), the two profiles had a sensitivity ranging from 60.6% to 72.7%, whereas the specificity ranged from 68.0% to 78.4%. Nonadherence at the 1-year visit was associated with an increased risk for early breast cancer events (HR, 2.97; 95% CI, 1.08-8.15), adjusted for age and tumor characteristics. In conclusion, two clinical profiles predicted early nonadherence and may allow for targeted interventions to increase adherence if validated in an independent cohort. Cancer Prev Res; 5(5); 735-45. Ó2012 AACR.

show abstract

Section: Discussionmentioning

confidence: 75%

“…Previous publications suggest nonadherence as high as 23.6% after the first year of follow-up (11,12). Nonadherence increases with each consecutive year (11,12).…”

Section: Introductionmentioning

confidence: 89%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Clinical Profiles Predict Early Nonadherence to Adjuvant Endocrine Treatment in a Prospective Breast Cancer Cohort

Markkula

Hietala

Henningson

et al. 2012

Cancer Prevention Research

View full text Add to dashboard Cite

show abstract

Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy

et al. 2021

View full text Add to dashboard Cite

IMPORTANCEEarly discontinuation of adjuvant endocrine therapy (ET) is problematic among breast cancer survivors, with previous studies suggesting that up to 50% of women do not adhere to the recommended full 5 years of ET treatment. OBJECTIVE To identify the association between early discontinuation of ET in the TrialAssigning Individualized Options for Treatment (TAILORx) and modifiable risk factors, polypharmacy, and types of additional medications such as antidepressants and opioids. DESIGN, SETTING, AND PARTICIPANTSThis post hoc analysis includes a subgroup of 954 patients with breast cancer in TAILORx, a randomized clinical trial conducted from April 7, 2006, to October 6, 2010. All participants received a diagnosis of hormone receptor-positive, ERBB2-negative, axillary node-negative breast cancer and started ET within a year of study entry. Analyses were conducted in the intent-to-treat population.

show abstract

Pharmacy‐Based Medical Record Linkage Systems

Herings¹,

Pedersen²

2012

Pharmacoepidemiology

View full text Add to dashboard Cite

Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis

Cited by 123 publications

References 26 publications

Clinical Profiles Predict Early Nonadherence to Adjuvant Endocrine Treatment in a Prospective Breast Cancer Cohort

Clinical Profiles Predict Early Nonadherence to Adjuvant Endocrine Treatment in a Prospective Breast Cancer Cohort

Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy

Pharmacy‐Based Medical Record Linkage Systems

Contact Info

Product

Resources

About